Background {#Sec1}
==========

In modern radiation therapy, intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic ablative radiotherapy (SABR) are used for precise radiation delivery \[[@CR1], [@CR2]\]. These techniques can generate a sophisticated dose distribution, delivering high doses to the target with lower doses to critical organs. Such dose distributions are delivered using a beam sequence with various degrees of freedom to address an increasingly conformal dose distribution \[[@CR3]\]. Therefore, they require a comprehensive quality assurance (QA) testing to verify the dose delivery \[[@CR4]--[@CR6]\]. These QA methods can detect possible errors, which can cause serious side effects for patients \[[@CR7], [@CR8]\]. Hence, pretreatment patient-specific dosimetry is essential \[[@CR9]\].

In recent decades, IMRT verification techniques have been developed to increase the efficiency and accuracy of associated QA procedures \[[@CR10]\]. Plan verification is generally performed using detector array systems, ion chamber, or film before first treatment. However, such pretreatment plan verifications have certain limitations \[[@CR11], [@CR12]\]. Verification is performed only once without the patient and before the first fraction on the assumption that the dose is delivered with no change or error over the course of treatment. However, this approach does not ensure that the planned dose is delivered to the patient during all treatment fractions because the mechanical conditions of the treatment machine can vary.

In modern radiotherapy, the focus has shifted toward adaptive radiotherapy, and an increasing demand for online dose verification of dose delivery has been observed \[[@CR13]\]. Dose-distribution prediction by analyzing the machine delivery log file has been introduced for online dose verification \[[@CR14]\]. Reconstructed three-dimensional (3D) dose verification models have also been developed for the same purpose \[[@CR15]--[@CR17]\]. In other ways, the 3D dose has been reconstructed from a computed tomography (CT) dataset based on measurement data and 3D dose calculation software \[[@CR18]\].

Accordingly, transmission detectors have been developed to address these demands, and several commercial products are now available for clinical purposes (e.g., IQM (iRT Systems GmbH, Koblenz, Germany), OCTAVIUS III DAVID (PTW Freiburg GmbH, Freiburg, Germany), Delta4 Discover (ScandiDos AB, Uppsala, Sweden), and the Dolphin online monitoring system (IBA Dosimetry, Schwarzenbruck, Germany) \[[@CR11], [@CR19], [@CR20]\].

Dolphin is a monitoring system with transmission detectors. The measurement data can be reconstructed to a 3D dose distribution on a 3D-CT image set using COMPASS software (IBA Dosimetry, Schwarzenbruck, Germany) \[[@CR21], [@CR22]\]. Dolphin can be used for pretreatment QA as well as during each fraction. However, Dolphin has some shortcomings, such as beam hardening scatter and electron contamination \[[@CR11]\]. Dolphin has a technical potential function for online dosimetry, which can be performed by mounting a detector on the gantry during treatment \[[@CR15]\]; however, it is not allowed for Dolphin. Note that in treatment planning, the dose is calculated without considering the attenuation by the detector. The transmission detector is located between the beam source and the patient \[[@CR12]\], and the radiation beam is perturbed by the material and thickness of the transmission detector \[[@CR23]\]. Until now, the treatment planning system (TPS) cannot address the beam attenuation factor of the transmission detector when a transmission detector is installed for online dosimetry. In other words, TPS does not support plan optimization and dose calculation for Dolphin. Therefore, the use of Dolphin in actual treatments is restricted \[[@CR9]\].

Cheung et al. recently presented the square field transmission factors for 6 MV, 6 flattening filter free (FFF), 10 MV, and 10 FFF clinical beams. These factors were previously available only for the static field used in 3D conformal radiotherapy. However, online dosimetry is more important for IMRT and VMAT \[[@CR11]\]. The dosimetric leaf gap (DLG) and the multileaf collimator (MLC) transmission are important parameters for the optimization and dose calculation of intensity-modulated fields delivered by the MLC \[[@CR24]\].

This study derived transmission factors of the Dolphin online monitoring system for IMRT and VMAT plan using 6 MV, 6 FFF, 10 MV, and 10 FFF clinical beams. We generated a normalized plan, which was normalized by transmission factors. To verify the transmission factors, the gamma index of the normalized plan was evaluated using two independent QA devices. In addition, the DLG and MLC transmission factors were individually measured to confirm the change of their characteristics by the Dolphin system for each available energy.

Methods {#Sec2}
=======

Transmission detector {#Sec3}
---------------------

The Dolphin transmission detector was a 2D array with 1513 plane-parallel ionization chambers. The volume of each chamber was 0.016 cm^3^ (diameter: 3.2 mm, height: 2 mm). The chambers were arranged with a 5 mm spacing in the central area (i.e., within the inner 15 × 15 cm^2^ region) and with a 10 mm spacing in the outer detector area (i.e., corresponding size in the isocenter plane: chamber diameter: 4.89 mm, 7.63 mm, and 15.26 mm spacing in the central and outer area, respectively).

The physical size of the detector was 24.3 × 24.3 cm^2^. A field size of up to 40 × 40 cm^2^ can be measured by installing the interface mount on the gantry head (at 65.5 cm from the source for TrueBeam STx system (Ver. 2.5, Varian Medical Systems, Inc., Palo Alto, CA)). The device incorporates a copper buildup plate with 1.5 mm thickness \[[@CR11]\].

Measurement setup and energies {#Sec4}
------------------------------

Figure [1](#Fig1){ref-type="fig"} shows the basic measurement setup involving the Dolphin detector and a linear accelerator. All measurements were conducted using the TrueBeam STx system equipped with a high-definition 120-leaf multileaf collimator. The four energies (i.e., 6 MV, 6 FFF, 10 MV, and 10 FFF) were used for the transmission factor measurement. The COMPASS software was not commissioned for 15 MV; therefore, 15 MV was excluded from the transmission factor measurement. Table [1](#Tab1){ref-type="table"} lists the values of the depth of maximum dose (***D***~**max**~), the percentage depth dose at 10 cm depth (***PDD***~**10**~), and tissue phantom ratio at the depths of 20 and 10 cm (***TPR*** **20/10**) with and with Dolphin for the four examined energies.Fig. 1Measurement device and linear accelerator: transmission detector and TrueBeam STxTable 1Depth of maximum dose (*D*~max~) and percentage depth dose at 10 cm depth (*PDD*~10~)Energy^a^*D*~max~ (cm)^b^*PDD*~10~ (%)^d^*TPR* 20/10With DolphinWithout DolphinWith DolphinWithout DolphinWith DolphinWithout Dolphin6 MV1.51.566.266.10.6680.6676 ^c^FFF1.31.363.263.00.6330.63210 MV2.12.173.673.50.7390.73710 FFF2.32.370.970.60.6940.692^a^*D*~*max*~ depth of maximum dose, ^b^*PDD*~10~ percentage depth dose at 10 cm depth, ^c^*FFF* flattening filter free, and ^d^*TPR* 20/10 tissue phantom ratio at the depths of 20 and 10 cm

Transmission factor and output factor measurements for square fields {#Sec5}
--------------------------------------------------------------------

The transmission factors of regular square fields were measured to evaluate the field size dependency. The transmission factor measurement was performed with 0.125-cc ionization chambers (TN31010, PTW, Freiburg, Germany) and an electrometer (Uniods E, PTW, Freiburg, Germany) in a solid water phantom (SWP, Virtual Watert™, Radiation Products Design, Inc., Albertville, MN) for various square fields (i.e., 3 × 3, 5 × 5, 7 × 7, 9 × 9, 10 × 10, 12 × 12, 15 × 15, and 20 × 20 cm^2^) and four energies. The SWP measured 30 × 30 cm^2^. The backscatter material behind the chamber was 5 cm thick of the SWP. The ionization chambers were located at the isocenter with a 5 cm depth for all energies. The output factors were also measured for eight square fields and four energies with and without Dolphin. The output factors were normalized to a 10 × 10 cm^2^ field size.

Dosimetric leaf gap and multileaf collimator transmission factor {#Sec6}
----------------------------------------------------------------

The DLG and the transmission factor of the MLC were examined to verify the IMRT and VMAT plans with and without Dolphin. The DLG was calculated by extrapolating the measurements of sweeping gap fields with varying widths (i.e., 2, 4, 6, 10, 14, 16, and 20 mm) \[[@CR25]\]. The MLC transmission ratio was defined as the ratio of the dose in the MLC leaves to the open field dose, which was calculated with and without Dolphin.

Dolphin transmission factors using IMRT and VMAT plans {#Sec7}
------------------------------------------------------

Subsequently, 10 IMRT and 10 VMAT plans were randomly selected for the four energies to calculate the transmission factors of the clinical beams. Each IMRT plan included five fields. VMAT plans with full and partial arcs were selected. IMRT and VMAT plans for various treatment sites (i.e., brain, head and neck, lung, spine, abdomen, and pelvic region) were chosen with delivery doses of 1.8--17 Gy. Four of the VMAT plans were generated for SABR. The jaw size was approximately 9 × 9 cm^2^ to 25 × 25 cm^2^ for both IMRT and VMAT plans. For SABR, the jaw size was approximately 3 × 3 cm^2^ to 6 × 6 cm^2^. A jaw tracking option was not applied.

All the IMRT and VMAT plans were generated by Eclipse 13.7 (Varian Medical Systems, Inc., Palo Alto, CA) based on the Acuros XB algorithm. A patient-specific verification plan was created based on the clinical patient plan to use the portal dosimetry system. Verification plans have a predicted fluence map on the electronic portal imaging device (EPID). The predicted fluence map can be compared with the measured fluence map by the EPID. The portal dose image prediction (PDIP, Ver 13.7, Varian Medical Systems, Inc., Palo Alto, CA) algorithm was used for portal dosimetry.

The transmission factors of the clinical beams were measured via portal dosimetry and an ArcCheck detector (Sun Nuclear Corporation (SNC), Melbourne, FL) using SNC patient software (Ver. 6.6, SNC, Melbourne, FL). An aS1200 EPID was used for portal dosimetry. The active area of the EPID was 40 × 40 cm^2^ for portal dosimetry, with a 0.336 mm resolution 2D pixel array (1190 × 1190) \[[@CR26]\]. The EPID was placed in the isocenter plane for measurement. Portal dosimetry was performed for the 25 × 25 cm^2^ field size with and without Dolphin to investigate the perturbation of measurement by the interior design of Dolphin. The uniformity was compared to two square dose distributions of EPID. The uniformity was defined as the average difference dose distribution relatively with and without Dolphin for pixel by pixel in 80% area of the field size.

Transmission factor calculation and verification for IMRT and VMAT {#Sec8}
------------------------------------------------------------------

The transmission factors were calculated as follows using the non-negative least-squares (NNLS) problem solver (Fig. [2](#Fig2){ref-type="fig"}(1)) \[[@CR27]\]:$$\documentclass[12pt]{minimal}
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where, *D*~*wo* \_ *dolphin*~ (Fig. [2b](#Fig2){ref-type="fig"}) is the dose distribution (2D matrix) measured without the Dolphin detector; *TF* is the transmission factor defined as the ratio of the transmitted radiation intensity to the incident radiation intensity; *D*~*w* \_ *dolphin*~ (Fig. [2a](#Fig2){ref-type="fig"}) is the dose distribution measured with the Dolphin; and ‖·‖~2~ denotes the Euclidean norm. The transmission factors were calculated for each field for all plans. Furthermore, the calculated transmission factors of all fields were averaged for each energy. The dose difference between and *D*~*w* \_ *dolphin*~ and *D*~*wo* \_ *dolphin*~ × *TF* (Fig. [2c](#Fig2){ref-type="fig"}) was calculated for each dose distribution to verify the transmission factors. The in-house program developed using MATLAB (R2015b, MathWorks, USA) was used for the NNLS calculation to obtain the average of the transmission factors and the dose difference between the dose matrices (Fig. [2](#Fig2){ref-type="fig"}. (2)).

The transmission factors were verified by measurement. For verification, normalized plans were generated by normalizing the original plan. This normalization was performed using the changing normalization value of the plan normalization mode in Eclipse. The normalization values were obtained by multiplying the original normalization value by the transmission factor of each energy (Fig. [2](#Fig2){ref-type="fig"} (3)). After normalization, the monitoring unit (MU) of the normalized plans was equal to the MU of the original plans multiplying normalization values.

A patient-specific QA of the normalized plans was performed using portal dosimetry and an ArcCheck detector. The dose difference and the gamma index were evaluated. The dose difference between the two plans was calculated, excluding the below-10% dose. Two criteria were applied for the gamma analysis: 2% dose difference (DD) and 2 mm distance to agreement (DTA) and 1% DD and 1 mm DTA. The threshold was set to 10% dose.

The gamma values were calculated to compare the QA results for the original plan and the normalized plan with the Dolphin detector for both QA devices (e.g., portal dosimetry and ArcCheck). The gamma index evaluation was performed for the predicted dose of the original plan and the measurement for the normalized plan with the Dolphin detector.

Results {#Sec9}
=======

Transmission factor and output factor measurements for square fields {#Sec10}
--------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} lists the measured Dolphin transmission factors for various square fields and each beam energy. The measured transmission factors for a 10 × 10 cm^2^ field size were 0.893, 0.883, 0.914, and 0.906 for the 6 MV, 6 FFF, 10 MV, and 10 FFF cases, respectively. For the square field, the measured transmission factors decreased with the increasing field size. Table [3](#Tab3){ref-type="table"} lists the output factors for various square fields and each beam energy with and without Dolphin. The relative photon outputs without Dolphin exhibited a larger variation compared to those with Dolphin. The output factors had a larger range with a decreasing energy.Table 2Measured Dolphin transmission factors for the square fields and each beam energyField size (cm^2^)Beam energy6 MV6 ^a^FFF10 MV10 FFF3 × 30.9460.9350.9480.9415 × 50.9320.9210.9360.9287 × 70.9160.9040.9250.9179 × 90.9010.8900.9200.91110 × 100.8930.8830.9140.90612 × 120.8870.8730.9090.90215 × 150.8770.8630.9030.89620 × 200.8660.8540.8970.891^a^*FFF* flattening filter freeTable 3Output factors for the square fields and each beam energy with and without DolphinField size (cm^2^)Beam energyOutput factor with DolphinOutput factor without Dolphin6 MV6 ^a^FFF10 MV10 FFF6 MV6 FFF10 MV10 FFF3 × 30.8820.8970.8810.9190.8330.8470.8490.8865 × 50.9300.9410.9360.9630.8920.9020.9140.9407 × 70.9660.9710.9680.9810.9420.9490.9560.9709 × 90.9910.9910.9910.9950.9820.9840.9840.99010 × 101.0001.0001.0001.0001.0001.0001.0001.00012 × 121.0191.0121.0161.0081.0261.0241.0211.01315 × 151.0391.0281.0341.0171.0591.0511.0461.02920 × 201.0681.0481.0571.0291.1021.0841.0771.047^a^*FFF* flattening filter free

Dolphin transmission factors using IMRT and VMAT plans {#Sec11}
------------------------------------------------------

Table [4](#Tab4){ref-type="table"} presents the MLC transmission factor and the DLG for each beam energy with and without Dolphin. The difference in the MLC transmission factors with and without Dolphin was within 1% for all energies. The DLG factors were almost identical with and without Dolphin. The maximum difference was 0.05 mm, which was obtained for 6 MV.Table 4MLC transmission factors and DLG for each beam energy with and without DolphinEnergy^a^MLC transmission factor^b^DLG (mm)MLC transmission factorDLG (mm)With DolphinWithout Dolphin6 MV0.0170.420.0110.376 ^c^FFF0.0140.280.0060.2410 MV0.0220.450.0130.510 FFF0.0190.380.0090.35^a^*MLC* multileaf collimator, ^b^*DLG* dosimetric leaf gap, and ^c^*FFF* flattening filter free

Dolphin transmission factors using IMRT and VMAT plans {#Sec12}
------------------------------------------------------

Figure [2a](#Fig2){ref-type="fig"} and [b](#Fig2){ref-type="fig"} show the measured dose distribution obtained via portal dosimetry with and without Dolphin, respectively, to represent the VMAT case. Figure [3a](#Fig3){ref-type="fig"} depicts the profile of each dose distribution. As a relative comparison, the dose distribution and the profile were almost identical. However, in absolute comparison, they exhibited remarkable differences. Table [5](#Tab5){ref-type="table"} lists the transmission factors for each energy and technique, which are the averages of the transmission factors calculated for each plan using Eq. (1). The differences between the IMRT and VMAT transmission factors were negligible. The average values were 0.878, 0.825, 0.913, and 0.883 for the 6 MV, 6 FFF, 10 MV, and 10 FFF cases, respectively.Fig. 3Dose profile: **a**) measured dose profile of the original plan with and without Dolphin (X-direction with Dolphin: black line, X-direction without Dolphin: red line, Y-direction with Dolphin: green line, and Y-direction without Dolphin: blue line) and **b**) dose distribution normalized by the transmission factor (TF) without Dolphin measurement (X-direction without Dolphin: green line, X-direction of the normalized dose: cyan line, Y-direction without Dolphin: blue line, and Y-direction of normalized dose: magenta line) (measurement value: calibration unit (CU))Table 5Calculated transmission factors for IMRT, VMAT, and SABREnergy^a^IMRT^b^VMAT^c^SABR6 MV0.878 ± 0.0020.877 ± 0.0020.878 ± 0.0066 ^d^FFF0.825 ± 0.0030.823 ± 0.0010.827 ± 0.00710 MV0.912 ± 0.0030.914 ± 0.0010.913 ± 0.00910 FFF0.883 ± 0.0020.882 ± 0.0030.885 ± 0.005^a^*IMRT* intensity-modulated radiation therapy, ^b^*VMAT* volumetric modulated arc therapy, ^c^*SABR* stereotactic ablative radiotherapy, and ^d^*FFF* flattening filter free

The standard deviation was in the range of 0.1--0.3%. The maximum variation between the calculated transmission factors was less than 0.8% for all energies for VMAT and IMRT.

Figure [2c](#Fig2){ref-type="fig"} shows the dose distribution obtained with normalization by the transmission factor. Figure [3b](#Fig3){ref-type="fig"} illustrates the dose profile comparison between the original and normalized plans. The average dose difference between measurement and expectation was below 0.8%, whereas the maximum was 1.3%.

The uniformity of the 25 × 25 cm^2^ field was 0.8% with and without Dolphin. The dose distributions were approximately identical.

Transmission factor verification {#Sec13}
--------------------------------

Figure [2d](#Fig2){ref-type="fig"} shows the measurement results using the new VMAT plan (i.e., normalized by the transmission factor) with Dolphin. The dose distribution was nearly identical to that of the measurement result delivered by the original plan without Dolphin (Fig. [2b](#Fig2){ref-type="fig"}). Figure [4](#Fig4){ref-type="fig"} presents the dose profile of the predicted dose of the original plan and the measured portal dosimetry dose of the normalized plan. The dose difference was below 1.8%. Figure [5a](#Fig5){ref-type="fig"} shows the dose distribution of the original plan measured by ArcCheck without Dolphin, while Fig. [5b](#Fig5){ref-type="fig"} depicts the dose distribution of the normalized plan measured by ArcCheck with Dolphin. Figure [6](#Fig6){ref-type="fig"} shows the measured dose profiles given by ArcCheck.Fig. 4Dose profile for the predicted dose of the original plan and the measurement dose of the normalized plan with Dolphin for verification: X-direction of the predicted dose of original plan: dark green line; X-direction of the measurement dose of the normalized plan with Dolphin: violet line; Y-direction of the predicted dose of the original plan: orange line; and Y-direction of the measurement dose of the normalized plan with Dolphin: purple line (measurement value: calibration unit (CU))Fig. 5Dose distributions measured by ArcCheck: **a**) original plan without Dolphin and **b**) normalized plan with Dolphin (measurement value: dose (cGy))Fig. 6Dose profiles measured by ArcCheck: the red circles and the black line indicate the original and normalized plans, respectively (measurement value: dose (cGy))

Table [6](#Tab6){ref-type="table"} lists the gamma passing rate of the original plan without Dolphin and the normalized plans with Dolphin. The gamma passing rate for all the original and normalized plan measurements obtained through portal dosimetry and with ArcCheck was above 90% with a 2%/2 mm criterion. The minimum gamma passing rate for the original plan verification with the 2%/2 mm criterion was 91.2% with ArcCheck. The maximum was 100% for both portal dosimetry and ArcCheck. Meanwhile, the gamma passing rate for the original plan verification with a 1%/1 mm criterion ranged between 69.1--99.5% and 57.2--98.2% for portal dosimetry and ArcCheck, respectively.Table 6Gamma passing rates of the transmission factor verification measurements in the clinical plans (unit: %)CriteriaOriginal plan without Dolphin\
Average ± standard deviation (range)Normalized plan with Dolphin\
Average ± standard deviation (range)Portal dosimetryArcCheckPortal dosimetryArcCheck2%/2 mm98.1 ± 2.1 (95.2 \~  100)97.3 ± 3.2 (91.2 \~  100)97.2 ± 2.8 (94.3 \~  98.2)96.9 ± 2.9 (90.1 \~  98.3)1%/1 mm82.9 ± 12.6 (69.1 \~  99.5)81.4 ± 15.3 (57.2 \~  98.2)79.1 ± 14.8 (73.2 \~  98.3)75.8 ± 18.8 (61.9 \~  94.3)

The minimum gamma passing rate for the ArcCheck measurements for the normalized plan verification with a 2%/2 mm criterion was 90.1%, while the maximum values were 98.2% and 98.3% for portal dosimetry and ArcCheck, respectively. For the SABR plan using portal dosimetry, the gamma passing rate of the original plan without Dolphin was 95.2--97.5% and 69.1--88.1% with 2%/2 mm and 1%/1 mm, respectively. The gamma passing rate of the normalized plan with Dolphin was 94.3--96.1% and 73.2--87.3% with 2%/2 mm and 1%/1 mm, respectively.

Discussion {#Sec14}
==========

In modern radiotherapy, online dosimetry has the potential to improve the accuracy and safety of delivery \[[@CR15]\]. Dolphin allows online dosimetry because of the transmission-type detector \[[@CR11]\]. Moreover, a 3D dose verification can be performed using Dolphin with COMPASS software \[[@CR21], [@CR22]\]. However, Eclipse does not support plan optimization and dose calculation for Dolphin. Therefore, the use of Dolphin in actual treatments is restricted \[[@CR9]\].

This study measured the transmission factors of all examined beam energies (6 MV, 6 FFF, 10 MV, and 10 FFF) for various square field sizes. The measured transmission factors varied from 3 × 3 to 20 × 20 cm^2^ for all beam energies. However, in IMRT and VMAT, the change in the field size has been extreme, and small field sizes are generally used for treatment \[[@CR28]\]. Therefore, the transmission factors measured for the square field sizes cannot be applied to IMRT, VMAT, or SABR for clinical purposes.

In this work, the MLC transmission factor and the DLG with and without Dolphin were investigated prior to patient-specific QA based on clinical IMRT and VMAT plans. The differences between the values with and with Dolphin were not significant for the MLC transmission factor. For a relative comparison of the QA result, the differences between with and without Dolphin were negligible in the low-dose area. In addition, the DLG was not affected by the detector because the dose profiles were similar in the high-dose gradient region. Such a small difference of the DLG can be neglected \[[@CR29]\]. Therefore, the same DLG value was used for the dose calculation.

This study derived the transmission factors provided by Dolphin for actual treatment plans and selected various plans for the measurements. For a relative comparison, the dose distributions were almost identical for measurements with and without the transmission detector. In contrast, an absolute comparison revealed large differences in the dose value because of the attenuation of the detector.

Table [5](#Tab5){ref-type="table"} shows that the transmission factors were affected by the beam energy only. The delivery technique, MU, and arc range did not influence the transmission factor. Our results showed a maximum difference of 0.8% for the four energies in each transmission factor.

In deriving the transmission factors, the non-negative least-squares problem solver calculated approximately 150,000--850,000 points for each field. The transmission factors of all fields were similar for the same energy. The dose distributions normalized by the transmission factors were also similar to the dose distributions transmitted by Dolphin.

The detector design and the electronic parts inside Dolphin were not uniform \[[@CR11]\]. However, each point had similar transmission factors. The maximum dose difference was below 1.7%. Portal dosimetry had a higher resolution than Dolphin because of the detector size of the EPID panel. The interior design of Dolphin did not affect the transmission factors.

The gamma passing rates of the patient-specific verification demonstrated that the plans normalized by the transmission factor can be applied for clinical purposes when a clinically acceptable criterion (i.e., 2%/2 mm) is used \[[@CR10]\]. For the SABR plan, the gamma passing rates of the original and normalized plans were poor with the 1%/1 mm criterion because SABR had small fields and high-gradient dose profiles. However, the gamma passing rates of both original and normalized plans were above 90% for all cases when 2%/2 mm criteria were applied. The gamma passing rates of the SABR plans were also within an acceptable range (i.e., above 90%) for clinical purposes.

Conclusions {#Sec15}
===========

This study derived the transmission factor of the Dolphin detector through the measurement of clinical IMRT and VMAT plans. The transmission factors were determined for four energies. However, these factors can vary for nominal energies. This study verified only the transmission factors for the beams of our machine; hence, we recommend the verification of the transmission factors for the beams of each individual machine before clinical use. The Dolphin detector can be an excellent device for online dosimetry if verified transmission factors are used.
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